Bod secures first binding purchase order for US market

•  Maiden ~A$312,000 purchase order received for first consumer CBD products to be launched in USA initially through ecommerce channels
•  More purchase orders for the US market are expected – Bod fully funded for product manufacturing requirements
•  US consumer CBD products market valued at US$1.8Bn in 2020 and expected to grow to US$6.9Bn by 2025i
•  Regulatory approval process complete – Bod’s CBD extract has achieved Self-Affirmed ‘Generally Recognised as Safe’ (GRAS) status in line with US FDA guidelines

i Report: Hemp Industry Daily: How to navigate the complicated world of CBD in retail - 2020

DISC: I hold

Leading medical advisory board established to capitalise on TGA decision to reschedule cannabis

? Members include Academic Director of the Lambert Initiative Prof. Iain McGregor, Head of Neurology at Gold Coast University Hospital Assoc. Prof. Arman Sabet, Dean of Sydney Pharmacy School Prof. Andrew McLachlan AM and ex Cancer Council CEO Prof. Ian Olver AM

? Board appointment coincides with the Therapeutic Goods Administration’s decision dated 15 December 2020 to down schedule CBD products to Scheduled 3 (pharmacist only) medicines

? Decision allows for low dose cannabidiol (CBD) products containing up to 150mg/day to be sold over-the-counter to consumers without a prescription

? Development broadens Bod’s addressable market and will assist with CBD product uptake across Australia ? Board’s immediate focus will be to review and evaluate the product registration pathways

LGP has also put out an announcement this morning re TGA decision to reschedule cannabis.

Disc : I have small holdings in both